Cargando…
Target-specific compound selectivity for multi-target drug discovery and repurposing
Most drug molecules modulate multiple target proteins, leading either to therapeutic effects or unwanted side effects. Such target promiscuity partly contributes to high attrition rates and leads to wasted costs and time in the current drug discovery process, and makes the assessment of compound sel...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549418/ https://www.ncbi.nlm.nih.gov/pubmed/36225560 http://dx.doi.org/10.3389/fphar.2022.1003480 |
_version_ | 1784805666188165120 |
---|---|
author | Wang, Tianduanyi Pulkkinen, Otto I. Aittokallio, Tero |
author_facet | Wang, Tianduanyi Pulkkinen, Otto I. Aittokallio, Tero |
author_sort | Wang, Tianduanyi |
collection | PubMed |
description | Most drug molecules modulate multiple target proteins, leading either to therapeutic effects or unwanted side effects. Such target promiscuity partly contributes to high attrition rates and leads to wasted costs and time in the current drug discovery process, and makes the assessment of compound selectivity an important factor in drug development and repurposing efforts. Traditionally, selectivity of a compound is characterized in terms of its target activity profile (wide or narrow), which can be quantified using various statistical and information theoretic metrics. Even though the existing selectivity metrics are widely used for characterizing the overall selectivity of a compound, they fall short in quantifying how selective the compound is against a particular target protein (e.g., disease target of interest). We therefore extended the concept of compound selectivity towards target-specific selectivity, defined as the potency of a compound to bind to the particular protein in comparison to the other potential targets. We decompose the target-specific selectivity into two components: 1) the compound’s potency against the target of interest (absolute potency), and 2) the compound’s potency against the other targets (relative potency). The maximally selective compound-target pairs are then identified as a solution of a bi-objective optimization problem that simultaneously optimizes these two potency metrics. In computational experiments carried out using large-scale kinase inhibitor dataset, which represents a wide range of polypharmacological activities, we show how the optimization-based selectivity scoring offers a systematic approach to finding both potent and selective compounds against given kinase targets. Compared to the existing selectivity metrics, we show how the target-specific selectivity provides additional insights into the target selectivity and promiscuity of multi-targeting kinase inhibitors. Even though the selectivity score is shown to be relatively robust against both missing bioactivity values and the dataset size, we further developed a permutation-based procedure to calculate empirical p-values to assess the statistical significance of the observed selectivity of a compound-target pair in the given bioactivity dataset. We present several case studies that show how the target-specific selectivity can distinguish between highly selective and broadly-active kinase inhibitors, hence facilitating the discovery or repurposing of multi-targeting drugs. |
format | Online Article Text |
id | pubmed-9549418 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95494182022-10-11 Target-specific compound selectivity for multi-target drug discovery and repurposing Wang, Tianduanyi Pulkkinen, Otto I. Aittokallio, Tero Front Pharmacol Pharmacology Most drug molecules modulate multiple target proteins, leading either to therapeutic effects or unwanted side effects. Such target promiscuity partly contributes to high attrition rates and leads to wasted costs and time in the current drug discovery process, and makes the assessment of compound selectivity an important factor in drug development and repurposing efforts. Traditionally, selectivity of a compound is characterized in terms of its target activity profile (wide or narrow), which can be quantified using various statistical and information theoretic metrics. Even though the existing selectivity metrics are widely used for characterizing the overall selectivity of a compound, they fall short in quantifying how selective the compound is against a particular target protein (e.g., disease target of interest). We therefore extended the concept of compound selectivity towards target-specific selectivity, defined as the potency of a compound to bind to the particular protein in comparison to the other potential targets. We decompose the target-specific selectivity into two components: 1) the compound’s potency against the target of interest (absolute potency), and 2) the compound’s potency against the other targets (relative potency). The maximally selective compound-target pairs are then identified as a solution of a bi-objective optimization problem that simultaneously optimizes these two potency metrics. In computational experiments carried out using large-scale kinase inhibitor dataset, which represents a wide range of polypharmacological activities, we show how the optimization-based selectivity scoring offers a systematic approach to finding both potent and selective compounds against given kinase targets. Compared to the existing selectivity metrics, we show how the target-specific selectivity provides additional insights into the target selectivity and promiscuity of multi-targeting kinase inhibitors. Even though the selectivity score is shown to be relatively robust against both missing bioactivity values and the dataset size, we further developed a permutation-based procedure to calculate empirical p-values to assess the statistical significance of the observed selectivity of a compound-target pair in the given bioactivity dataset. We present several case studies that show how the target-specific selectivity can distinguish between highly selective and broadly-active kinase inhibitors, hence facilitating the discovery or repurposing of multi-targeting drugs. Frontiers Media S.A. 2022-09-23 /pmc/articles/PMC9549418/ /pubmed/36225560 http://dx.doi.org/10.3389/fphar.2022.1003480 Text en Copyright © 2022 Wang, Pulkkinen and Aittokallio. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wang, Tianduanyi Pulkkinen, Otto I. Aittokallio, Tero Target-specific compound selectivity for multi-target drug discovery and repurposing |
title | Target-specific compound selectivity for multi-target drug discovery and repurposing |
title_full | Target-specific compound selectivity for multi-target drug discovery and repurposing |
title_fullStr | Target-specific compound selectivity for multi-target drug discovery and repurposing |
title_full_unstemmed | Target-specific compound selectivity for multi-target drug discovery and repurposing |
title_short | Target-specific compound selectivity for multi-target drug discovery and repurposing |
title_sort | target-specific compound selectivity for multi-target drug discovery and repurposing |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549418/ https://www.ncbi.nlm.nih.gov/pubmed/36225560 http://dx.doi.org/10.3389/fphar.2022.1003480 |
work_keys_str_mv | AT wangtianduanyi targetspecificcompoundselectivityformultitargetdrugdiscoveryandrepurposing AT pulkkinenottoi targetspecificcompoundselectivityformultitargetdrugdiscoveryandrepurposing AT aittokalliotero targetspecificcompoundselectivityformultitargetdrugdiscoveryandrepurposing |